59 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
43
N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.
Boehringer Ingelheim Pharmaceuticals
17
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.
Bristol Myers Squibb
22
Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists.
AstraZeneca
57
The discovery of BMS-457, a potent and selective CCR1 antagonist.
Bristol Myers Squibb
27
Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists.
AstraZeneca
56
1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
Chemocentryx
23
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.
AstraZeneca
22
Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.
University of Copenhagen
67
Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.
Bristol Myers Squibb
63
Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.
Deltagen Research Laboratories (Former Combichem)
69
Identification of novel series of human CCR1 antagonists.
Tanabe Research Laboratories Usa
2
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Abbott Laboratories
21
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.
Novartis Institutes For Biomedical Research
22
CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.
Glaxosmithkline
10
Design and synthesis of a library of chemokine antagonists.
Novartis Institutes of Biomedical Research
14
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.
Telik
14
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
Incyte
21
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Università
19
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Genzyme
26
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Roche Palo Alto
22
A Fluorescent Probe Enables the Discovery of Improved Antagonists Targeting the Intracellular Allosteric Site of the Chemokine Receptor CCR7.
University of Bonn
32
Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.
Tanabe Research Laboratories
10
Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.
Pfizer
29
Structural Analysis of Chemokine Receptor-Ligand Interactions.
Vrije Universiteit Amsterdam
26
Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.
Merck Research Laboratories
11
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Takeda Pharmaceutical
11
Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
Ciimar
62
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
Pharmaceutical Research Institute
3
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.
Bristol Myers Squibb
15
The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template.
Pfizer
6
Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2.
Leiden Academic Centre For Drug Research
109
Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.
Bristol Myers Squibb
19
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.
Merck Research Laboratories
16
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.
Merck Research Laboratories
33
Design, synthesis, and discovery of a novel CCR1 antagonist.
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
47
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.
Merck Research Laboratories
8
Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds.
National Cancer Istitute-Frederick Cancer Research and Development Center
24
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
Takeda Chemical Industries
46
Discovery and optimization of pyrazole amides as antagonists of CCR1.
Boehringer Ingelheim Pharmaceuticals
36
Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.
Leiden University
50
Identification of novel azaindazole CCR1 antagonist clinical candidates.
Boehringer Ingelheim Pharmaceuticals
37
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
Glaxosmithkline
36
Identification of a novel series of potent and selective CCR6 inhibitors as biological probes.
Takeda Pharmaceutical
49
Identification and biological evaluation of thiazole-based inverse agonists of RORĪ³t.
Phenex Pharmaceuticals
4
Benzoimidazole derivatives as anticancer agents
Centre Leon Berard; Hospices Civils De Lyon; Universite Claude Bernard Lyon 1; Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Recherche Medicale (Inserm)